IL298542B2 - Solid dosage forms intended for treatment containing deuterium-containing N,N-dimethyltryptamine compounds and their salts - Google Patents
Solid dosage forms intended for treatment containing deuterium-containing N,N-dimethyltryptamine compounds and their saltsInfo
- Publication number
- IL298542B2 IL298542B2 IL298542A IL29854222A IL298542B2 IL 298542 B2 IL298542 B2 IL 298542B2 IL 298542 A IL298542 A IL 298542A IL 29854222 A IL29854222 A IL 29854222A IL 298542 B2 IL298542 B2 IL 298542B2
- Authority
- IL
- Israel
- Prior art keywords
- dimethyltryptamine
- solid dosage
- dosage form
- compounds
- disorder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/890,664 US11771681B2 (en) | 2019-06-03 | 2020-06-02 | Therapeutic compounds |
| GB2008303.6A GB2585978B (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions |
| PCT/EP2020/065244 WO2020245133A1 (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US17/108,938 US20220169606A1 (en) | 2020-12-01 | 2020-12-01 | Compositions and compounds for bioanalysis |
| GBGB2018950.2A GB202018950D0 (en) | 2020-12-01 | 2020-12-01 | Parenteral formulation |
| GBGB2018955.1A GB202018955D0 (en) | 2020-12-01 | 2020-12-01 | Compositions and compounds for bioanalysis |
| US17/108,679 US20220168274A1 (en) | 2020-12-01 | 2020-12-01 | Parenteral Formulation |
| US17/208,583 US11773062B2 (en) | 2021-03-22 | 2021-03-22 | Deuterated compounds |
| GB2103981.3A GB2605144A (en) | 2021-03-22 | 2021-03-22 | Deuterated compounds |
| PCT/EP2021/060750 WO2021116503A2 (en) | 2020-06-02 | 2021-04-23 | Deuterated compounds |
| PCT/EP2021/062794 WO2021244831A1 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL298542A IL298542A (en) | 2023-01-01 |
| IL298542B1 IL298542B1 (en) | 2024-10-01 |
| IL298542B2 true IL298542B2 (en) | 2025-02-01 |
Family
ID=76329655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL298542A IL298542B2 (en) | 2020-06-02 | 2021-05-13 | Solid dosage forms intended for treatment containing deuterium-containing N,N-dimethyltryptamine compounds and their salts |
Country Status (8)
| Country | Link |
|---|---|
| EP (3) | EP3902541B1 (enExample) |
| JP (1) | JP7579888B2 (enExample) |
| CN (1) | CN115996713A (enExample) |
| AU (1) | AU2021284861A1 (enExample) |
| CA (1) | CA3118556A1 (enExample) |
| GB (1) | GB2595776B (enExample) |
| IL (1) | IL298542B2 (enExample) |
| WO (2) | WO2021116503A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| KR20220082092A (ko) | 2019-11-07 | 2022-06-16 | 스몰 파마 엘티디 | 화합물 |
| KR20220137081A (ko) | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체 |
| BR112022015379A2 (pt) | 2020-02-04 | 2022-09-27 | Mindset Pharma Inc | Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc |
| WO2021226416A1 (en) | 2020-05-08 | 2021-11-11 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| EP4188492A4 (en) * | 2020-07-29 | 2024-08-07 | Gregory Ellis | DELIVERY SYSTEM FOR AYAHUSCA-LIKE SUBSTANCES |
| AU2021328671A1 (en) | 2020-08-18 | 2023-02-16 | Cybin Irl Limited | Phenethylamine derivatives, compositions, and methods of use |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| EP4031529B1 (en) * | 2020-12-01 | 2023-09-27 | Small Pharma Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| WO2022117640A1 (en) | 2020-12-01 | 2022-06-09 | Small Pharma Ltd | Inhalable formulations |
| EP4255422A4 (en) | 2020-12-03 | 2024-12-18 | Mydecine Innovations Group Inc. | NEW PSILOCIN ANALOGUE COMPOSITIONS AND METHODS OF THEIR SYNTHESIS |
| CA3218110A1 (en) | 2021-05-25 | 2022-12-01 | Majed Fawaz | New n,n-dimethyltryptamine salts and crystalline salt forms |
| AU2022287974A1 (en) | 2021-06-09 | 2024-01-04 | Atai Therapeutics, Inc. | Novel prodrugs and conjugates of dimethyltryptamine |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| EP4159201A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Encapsulated microparticles and nanoparticles of dimethyltriptamines |
| EP4433049A1 (en) | 2021-11-18 | 2024-09-25 | Cybin UK Ltd | Injectable and inhalable formulations |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| WO2023129956A2 (en) * | 2021-12-30 | 2023-07-06 | ATAI Life Sciences AG | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| EP4463440A1 (en) * | 2022-01-14 | 2024-11-20 | Cybin IRL Limited | Tryptamine compositions and methods |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| AU2023242469A1 (en) * | 2022-03-31 | 2024-09-05 | Cybin Irl Limited | Combination of nitrous oxide and 5-ht2a receptor agonists |
| AU2023269880A1 (en) | 2022-05-10 | 2024-01-18 | Mydecine Innovations Group Inc. | Novel psilocin prodrug compounds and methods of synthesizing the same |
| WO2024108195A1 (en) | 2022-11-17 | 2024-05-23 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019081764A1 (en) * | 2017-10-26 | 2019-05-02 | Consejo Superior De Investigaciones Científicas (Csic) | ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS |
| WO2020245133A1 (en) * | 2019-06-03 | 2020-12-10 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20010356A1 (it) | 2001-06-21 | 2002-12-23 | Sigma Tau Ind Farmaceuti | "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. |
| JP6367545B2 (ja) | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| KR20220082092A (ko) * | 2019-11-07 | 2022-06-16 | 스몰 파마 엘티디 | 화합물 |
-
2021
- 2021-04-23 EP EP21720509.5A patent/EP3902541B1/en active Active
- 2021-04-23 WO PCT/EP2021/060750 patent/WO2021116503A2/en not_active Ceased
- 2021-05-13 IL IL298542A patent/IL298542B2/en unknown
- 2021-05-13 EP EP24215587.7A patent/EP4494703A3/en active Pending
- 2021-05-13 AU AU2021284861A patent/AU2021284861A1/en active Pending
- 2021-05-13 CN CN202180046533.1A patent/CN115996713A/zh active Pending
- 2021-05-13 JP JP2022574098A patent/JP7579888B2/ja active Active
- 2021-05-13 WO PCT/EP2021/062794 patent/WO2021244831A1/en not_active Ceased
- 2021-05-13 CA CA3118556A patent/CA3118556A1/en active Pending
- 2021-05-13 EP EP21725377.2A patent/EP4149460B8/en active Active
- 2021-05-13 GB GB2106881.2A patent/GB2595776B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019081764A1 (en) * | 2017-10-26 | 2019-05-02 | Consejo Superior De Investigaciones Científicas (Csic) | ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS |
| WO2020245133A1 (en) * | 2019-06-03 | 2020-12-10 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
Non-Patent Citations (3)
| Title |
|---|
| BEATON J M ET AL,, A COMPARISON OF THE BEHAVIORAL EFFECTS OF PROTEO- AND DEUTERO-N, N-DIMETHYLTRYPTAMINE, 1 May 1982 (1982-05-01) * |
| MORRIS ET AL.,, INDOLEALKYLAMINE METABOLISM: SYNTHESIS OF DEUTERATED INDOLEALKYLAMINES AS METABOLIC PROBES, 31 December 1993 (1993-12-31) * |
| SIMON D. BRANDT ET AL,, MICROWAVE-ACCELERATED SYNTHESIS OF PSYCHOACTIVE DEUTERATED N , N -DIALKYLATED-[ [ALPHA] , [ALPHA] , [BETA] , [BETA] -D 4 ]-TRYPTAMINES, 1 November 2008 (2008-11-01) * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3902541B1 (en) | 2022-09-14 |
| WO2021116503A8 (en) | 2021-08-12 |
| JP7579888B2 (ja) | 2024-11-08 |
| EP4494703A2 (en) | 2025-01-22 |
| EP4149460B1 (en) | 2024-11-27 |
| EP4149460C0 (en) | 2024-11-27 |
| GB202106881D0 (en) | 2021-06-30 |
| WO2021116503A3 (en) | 2023-09-28 |
| CA3118556A1 (en) | 2021-12-02 |
| WO2021244831A1 (en) | 2021-12-09 |
| JP2023527575A (ja) | 2023-06-29 |
| WO2021116503A2 (en) | 2021-06-17 |
| EP4494703A3 (en) | 2025-04-02 |
| IL298542B1 (en) | 2024-10-01 |
| GB2595776B (en) | 2023-05-24 |
| AU2021284861A1 (en) | 2023-01-05 |
| CN115996713A (zh) | 2023-04-21 |
| GB2595776A (en) | 2021-12-08 |
| IL298542A (en) | 2023-01-01 |
| EP4149460A1 (en) | 2023-03-22 |
| EP3902541A2 (en) | 2021-11-03 |
| EP4149460B8 (en) | 2025-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL298542B2 (en) | Solid dosage forms intended for treatment containing deuterium-containing N,N-dimethyltryptamine compounds and their salts | |
| JP2023527575A5 (enExample) | ||
| JP2017203047A (ja) | ノルイボガインのリン酸エステル | |
| EP3436083A1 (en) | Novel compositions and methods | |
| Riederer et al. | Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia | |
| CA2339008A1 (en) | Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases | |
| JP2003503450A5 (enExample) | ||
| EP0844875B1 (en) | Use of basic l-carnitine and acyl derivatives for lowering ceramide levels | |
| JP2022526763A5 (enExample) | ||
| WO1998038999A1 (en) | The use of levobupivacaine in paediatric surgery | |
| JP2025509830A5 (enExample) | ||
| TW200410683A (en) | Medicament for preventing and/or treating peripheral neuropathies | |
| US5670524A (en) | Methods and compositions for the treatment of pain utilizing ropivacaine | |
| AU2006275824A1 (en) | Method of improving wakefulness | |
| IL298541B1 (en) | 1,1-dideuterio-2-(1H-indol-3-yl)-N,N-bis(trideuteriomethyl)ethanamine and a medical preparation containing it | |
| NZ794813B2 (en) | Therapeutic solid dosage forms | |
| US20130023535A1 (en) | Method of preventing and/or treating diabetic neuropathy | |
| NZ794813A (en) | Therapeutic solid dosage forms | |
| EP0429676B1 (en) | Drug for improving brain function | |
| CN116685316A (zh) | 用于治疗脂质相关失调的组合物和方法 | |
| Ban | Haloperidol and the butyrophenones | |
| Hoffman et al. | Cerebrovascular and cerebral metabolic effects of clurazepam and a benzodiazepine antagonist, 3-hydroxymethyl-β-carboline | |
| NZ783166A (en) | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| NZ783166B2 (en) | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| Yoshida et al. | Effect of THAM on brain oedema in experimental brain injury |